Eli Lilly has agreed to acquire three vaccine biotech companies—Curevo, LimmaTech Biologics, and Vaccine Company—for a combined value of up to $3.8 billion, with undisclosed but substantial upfront payments and future milestone-based payments.
The deals expand Lilly's infectious disease and vaccine portfolio, including a next-generation shingles vaccine (Curevo), bacterial vaccines (LimmaTech), and an Epstein–Barr virus and viral‑pathogen platform (Vaccine Company).
Infinimmune, a separate biotech, has raised $75 million in financing, likely to advance its immunology or autoantibody therapies, though the exact use of funds is not specified in the provided results.
Sources:
Lilly announces three acquisitions to build infectious disease portfolio
Eli Lilly Strikes Deal for Cancer Biotech
Eli Lilly bets $70M upfront and another $2B in biobucks for ...
Eli Lilly $3.8B Vaccine Acquisitions: Infectious Disease R&D
Lilly to acquire LimmaTech Biologics and Vaccine ...
Lilly lands vaccine trifecta with 3 new biotech buys valued at up to $3.8B
Lilly Continues Biotech Acquisition Spree
Lilly will buy 3 vaccine firms in 'power move' - C&EN
GC Biopharma secures KRW 286.8b from Lilly in Curevo sale, boosts Q3 profit - CHOSUNBIZ
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley ...
Eli Lilly to buy trio of vaccine makers for nearly $4B - LinkedIn
Lilly dives into vaccine research with 3 biotech buyouts - BioPharma Dive
Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next ...
Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues